Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Account Payables (2021 - 2025)

Amylyx Pharmaceuticals has reported Change in Account Payables over the past 5 years, most recently at $275000.0 for Q4 2025.

  • Quarterly results put Change in Account Payables at $275000.0 for Q4 2025, down 81.32% from a year ago — trailing twelve months through Dec 2025 was $580000.0 (up 103.04% YoY), and the annual figure for FY2025 was $580000.0, up 103.04%.
  • Change in Account Payables for Q4 2025 was $275000.0 at Amylyx Pharmaceuticals, up from -$33000.0 in the prior quarter.
  • Over the last five years, Change in Account Payables for AMLX hit a ceiling of $15.8 million in Q4 2023 and a floor of -$18.4 million in Q3 2023.
  • Median Change in Account Payables over the past 5 years was $61500.0 (2021), compared with a mean of -$5800.0.
  • Biggest five-year swings in Change in Account Payables: surged 2736.16% in 2022 and later tumbled 1570.57% in 2023.
  • Amylyx Pharmaceuticals' Change in Account Payables stood at $1.4 million in 2021, then tumbled by 157.72% to -$800000.0 in 2022, then soared by 2077.5% to $15.8 million in 2023, then plummeted by 90.7% to $1.5 million in 2024, then plummeted by 81.32% to $275000.0 in 2025.
  • The last three reported values for Change in Account Payables were $275000.0 (Q4 2025), -$33000.0 (Q3 2025), and -$1.5 million (Q2 2025) per Business Quant data.